Jumonji Family Antibody Sampler Kit

• 产品编号：CST-8340S      品牌：Cell Signaling Technology       原厂货号：8340S
• 产品分类：抗体 > 一抗 > 复合抗体试剂盒
• 应用分类：

其它组分：

描述：

Jumonji Family Antibody Sampler Kit中的每个抗体能够检测内源性各自靶蛋白水平。通过人工合成人源JARID1A蛋白、人源JARID1C蛋白Leu830位点周围残基、人源JMJD2A蛋白Val444位点残基或人源PHF2蛋白相应多肽去免疫动物从而制备出单克隆抗体。通过重组人源JMJD1B蛋白相应序列去免疫动物从而制备单克隆抗体。通过人工合成人源JARID1B蛋白或人源JMJD2B蛋白相应多肽片段去免疫动物从而制备出多克隆抗体。通过蛋白A和多肽亲和层析纯化多克隆抗体。Jumonji Family Antibody Sampler Kit提供了一个经济的方法去评估Jumonji蛋白家族总水平。该试剂盒包含充足的一抗，每种一抗可进行四次免疫印迹反应。包含蛋白质的Jumonji C (JmjC)区域代表最大的潜在组蛋白去乙酰化酶蛋白(1)。JmjC区域通过氧化反应能催化单、双和三甲基化的赖氨酸残基的去乙甲基化，这种氧化反应需要铁离子和α-酮戊二酸(1)。基于同源性，人源和小鼠都包含至少30种这样蛋白质，这能够被分为7个不同的家族(1)。JMJD2 (Jumonji domain-containing protein 2)家族也称为JHDM3 (JmjC domain-containing histone demethylation protein 3)家族，包含四个成员：JMJD2A/JHDM3A、JMJD2B/JHDM3B、JMJD2C/JHDM3C和JMJD2D/JHDM3D。除了JmJC结构域之外，这些蛋白质也包含JmJN、PHD和Tudor结构域，而后者基因证明能结合到甲基化的histone H3蛋白Lys4和Lys9 位点，以及甲基化的histone H4蛋白Lys20位点上(2,3)。研究证明JMJD2蛋白可以使双核三甲基化的histone H3蛋白Lys9和Lys36位点上去甲基化，并且具有转录的激活和抑制因子的功能(4-9)。JMJD2A、JMJD2C 和JMJD2D作为在前列腺肿瘤细胞中雄激素受体的共激活因子(5)。与此相反，JMJD2A也与Rb和N-CoR共抑制因子复合物有关联，并且对于靶基因的转录抑制是必须的(6,7)。在着丝点周围异染色质上JMJD2B蛋白抑制histone H3蛋白Lys9位点三甲基化(8)。JMJD1B蛋白是一个广泛表达的家族成员，并且在骨髓性白血病中频繁缺失(10)。JARID (Jumonji/AT-rich interactive domain-containing protein)家族包含四个成员：JARID1A (RBP2 和RBBP2)、JARID1B (PLU-1)、JARID1C (SMCX)和JARID1D (SMCY) (11)。除了JmJC区域之外，这些蛋白质包含JmJN、BRIGHT、C5HC2 zinc-finger和PHD结构域，后者能结合到甲基化的histone H3 (Lys9) (11)。所有四个JARID蛋白都是双甲基化和三甲基化 histone H3蛋白Lys4位点去甲基化； JARID1B蛋白也使单甲基化histone H3蛋白Lys4位点去甲基化(12-14)。JARID1A蛋白是一个关键RB-相互作用蛋白，并且在ES细胞分化期间对Polycomb-Repressive Complex 2 (PRC2)介导的转录抑制是需要的(15)。一个JARID1A-NUP98基因融合是与骨髓性白血病有关联(16)。JARID1B与许多蛋白质包括c-Myc和HDAC4相互作用，这可能通过封闭末端分化在细胞命运决策中起着一定作用(17-19)。JARID1B在许多乳腺癌中过表达，并且可能通过抑制多种肿瘤抑制基因包括BRCA1和HOXA5而发挥作用 (20,21)。JARID1C已经被发现在HDAC1、HDAC2、G9a和REST的复合物中，在非神经细胞中这结合到并且抑制REST靶基因(14)。JARID1D在很大程度上没有特征。PHF2包含一个JmjC结构域，该结构域在组蛋白去甲基化中起着重要作用(1)。

原厂资料：

Specificity / Sensitivity

Each antibody in the Jumonji Family Antibody Sampler Kit detects endogenous levels of the respective target protein.

Source / Purification

Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to human JARID1A protein, residues surrounding Leu830 of the human JARID1C protein, residues surrounding Val444 of human JMJD2A protein, or human PHF2 protein. Monoclonal antibodies are produced by immunizing animals with a recombinant protein derived from the sequence of human JMJD1B protein. Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to human JARID1B protein or human JMJD2B protein. Polyclonal antibodies are purified by protein A and peptide affinity chromatography.

Description

The Jumonji Family Antibody Sampler Kit provides an economical means of evaluating total levels of Jumonji family proteins. The kit contains enough primary antibodies to perform four western blot experiments with each primary antibody.

Background

Jumonji C (JmjC) domain-containing proteins represent the largest class of potential histone demethylase proteins (1). The JmjC domain can catalyze the demethylation of mono-, di-, and tri-methyl lysine residues via an oxidative reaction that requires iron and α-ketoglutarate (1). Based on homology, both humans and mice contain at least 30 such proteins, which can be divided into 7 separate families (1). 
 
 The JMJD2 (Jumonji domain-containing protein 2) family, also known as JHDM3 (JmjC domain-containing histone demethylation protein 3) family, contains four members: JMJD2A/JHDM3A, JMJD2B/JHDM3B, JMJD2C/JHDM3C, and JMJD2D/JHDM3D. In addition to the JmjC domain, these proteins also contain JmjN, PHD and Tudor domains, the latter of which has been shown to bind to methylated histone H3 at Lys4 and Lys9, and methylated histone H4 at Lys20 (2,3). JMJD2 proteins have been shown to demethylate di- and tri-methyl histone H3 at Lys9 and Lys36, and function as both activators and repressors of transcription (4-9). JMJD2A, JMJD2C and JMJD2D function as coactivators of the androgen receptor in prostate tumor cells (5). In contrast, JMJD2A also associates with Rb and N-CoR corepressor complexes and is necessary for transcriptional repression of target genes (6,7). JMJD2B antagonizes histone H3 Lys9 tri-methylation at pericentric heterochromatin (8). JMJD1B is a more widely expressed family member and is frequently deleted in myeloid leukemia (10). 
 
 The JARID (Jumonji/AT-rich interactive domain-containing protein) family contains four members: JARID1A (also RBP2 and RBBP2), JARID1B (also PLU-1), JARID1C (also SMCX), and JARID1D (also SMCY) (11). In addition to the JmjC domain, these proteins contain JmjN, BRIGHT, C5HC2 zinc-finger, and PHD domains, the latter of which binds to methylated histone H3 (Lys9) (11). All four JARID proteins demethylate di- and tri-methyl histone H3 Lys4; JARID1B also demethylates mono-methyl histone H3 Lys4 (12-14). JARID1A is a critical RB-interacting protein and is required for Polycomb-Repressive Complex 2 (PRC2)-mediated transcriptional repression during ES cell differentiation (15). A JARID1A-NUP98 gene fusion is associated with myeloid leukemia (16). JARID1B, which interacts with many proteins including c-Myc and HDAC4, may play a role in cell fate decisions by blocking terminal differentiation (17-19). JARID1B is over-expressed in many breast cancers and may act by repressing multiple tumor suppressor genes including BRCA1 and HOXA5 (20,21). JARID1C has been found in a complex with HDAC1, HDAC2, G9a, and REST, which binds to and represses REST target genes in non-neuronal cells (14). JARID1D is largely uncharacterized. PHF2 contains a JmjC domain, which may play a role in histone demethylation (1) .

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150
mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02%
sodium azide. Store at –20°C. Do not aliquot the antibodies.